Cargando…

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting both adults and children. To better understand the efficacy-safety profile of biologics in children with moderate-to-severe psoriasis, this study aimed to analyze efficacy and safety data of randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golhen, Klervi, Winskill, Carolyn, Theiler, Martin, Buettcher, Michael, Yeh, Yu-Hsin, Zhang, Nancy, Welzel, Tatjana, Pfister, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548699/ https://www.ncbi.nlm.nih.gov/pubmed/36226155 http://dx.doi.org/10.3389/fmed.2022.944208

Ejemplares similares

Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis
por: Golhen, Klervi, et al.
Publicado: (2022)

Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children
por: Golhen, Klervi, et al.
Publicado: (2023)

Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials
por: Welzel, Tatjana, et al.
Publicado: (2021)

Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials
por: Welzel, Tatjana, et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Melatonin as a Therapy for Preterm Brain Injury: What Is the Evidence?
por: Häusler, Silke, et al.
Publicado: (2023)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Tapering of biological treatment in autoinflammatory diseases: a scoping review
por: Welzel, Tatjana, et al.
Publicado: (2022)

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
por: Membrive Jiménez, Cristina, et al.
Publicado: (2021)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis
por: Messori, Andrea, et al.
Publicado: (2015)

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
por: Cline, Abigail, et al.
Publicado: (2019)

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
por: Vide, Júlia, et al.
Publicado: (2017)

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
por: Barker, Jonathan, et al.
Publicado: (2021)

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend
por: Saikaly, Sami K, et al.
Publicado: (2016)

Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives
por: Diotallevi, Federico, et al.
Publicado: (2022)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
por: Travaglini, Massimo, et al.
Publicado: (2023)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
por: Membrive-Jiménez, Cristina, et al.
Publicado: (2023)

Thiol/disulphide balance in patients with psoriasis
por: Aksoy, Mustafa, et al.
Publicado: (2020)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Beauty and the Biologic: Artistic Documentation of Scientific Breakthrough in Psoriasis
por: Maul, Julia-Tatjana, et al.
Publicado: (2015)

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Pediatric psoriasis: an update
por: Silverberg, Nanette B
Publicado: (2009)

Recent advances in understanding psoriasis
por: Eberle, Franziska C., et al.
Publicado: (2016)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015)

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
por: Geng, Wenjun, et al.
Publicado: (2018)

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2021)

Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohort PSOBIOTEQ
por: Curmin, R., et al.
Publicado: (2022)

Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis
por: Won, Sang-Hyeon, et al.
Publicado: (2023)

Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
por: Wang, Juncheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3omjkt8uq0jhumsc2je21ef2ta